Elevated plasma γ-aminobutyrate/glutamate ratio and responses to risperidone antipsychotic treatment in schizophrenia

Progress in Neuro-psychopharmacology & Biological Psychiatry
Hua-Lin CaiHai-Sen Ye

Abstract

γ-aminobutyrate (GABA) and Glutamate (Glu) are respectively two major inhibitory and excitatory neurotransmitters in the central nervous system and recent theories propose that both of their signaling complexes are compromised in patients with schizophrenia. The changes in plasma GABA, Glu and GABA/Glu ratio in schizophrenia have been studied and may be potential clinical markers. Here, we examined if plasma GABA, Glu and GABA/Glu ratio are altered in 32 schizophrenics, including a comprehensive investigation of their involvements with clinical course of a 6-week risperidone antipsychotic treatment. Plasma levels of GABA and Glu were significantly lower in patients than in controls, while plasma GABA/Glu ratio was significantly elevated. During treatment, a non-significant further decrease of plasma GABA, a significant increase of plasma Glu and a significant reduction of plasma GABA/Glu ratio were observed. The ratio returned to the control level at week 6 even though concentrations of GABA and Glu were still distant from normal. After the Bonferroni correction, partial correlation analyses showed that plasma GABA and GABA/Glu ratio were positively correlated with the dose of risperidone and plasma concentration of 9-hydroxyri...Continue Reading

References

Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Apr 1, 1984·Journal of Affective Disorders·F Petty, A D Sherman
Nov 1, 1993·The American Journal of Psychiatry·C A AltamuraF Zamberlan
Sep 1, 1993·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·F PettyA J Rush
Feb 15, 1996·Biological Psychiatry·F PettyC L Bowden
Dec 1, 1999·Molecular Psychiatry·F PettyA J Rush
Apr 12, 2002·Acta Psychiatrica Scandinavica·S GilbodyC Adams
Nov 19, 2003·Journal of Clinical Psychopharmacology·Adel WassefLisa D Kochan
Apr 2, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Veerle BerginkHerman G M Westenberg
Apr 2, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·F M M A van der HeijdenW M A Verhoeven
Sep 29, 2004·Biochemical Pharmacology·Joseph T Coyle
Jun 14, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Tohru OhnumaHeii Arai
Jun 15, 2006·Cellular and Molecular Neurobiology·Joseph T Coyle
Jul 11, 2006·Schizophrenia Research·Aitor PalominoCarlos Matute
Aug 25, 2009·Neurochemical Research·Aurora ArrúeJosé Guimón

❮ Previous
Next ❯

Citations

May 26, 2015·Neurological Research·Jacek KurzepaAnna Boguszewska-Czubara
May 15, 2016·Biochimica Et Biophysica Acta·Zhen QiEberhard O Voit
Dec 10, 2020·Scientific Reports·Camila Marcelino LoureiroPaulo Louzada-Junior
Dec 5, 2020·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Gonzalo M QuiñonesFabio Ferrarelli
Jan 18, 2021·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Tessa H de BieMichiel G J Balvers
Oct 8, 2021·Journal of Proteome Research·Gaoping CuiChunling Wan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here